Fidia Farmaceutici, SpA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fidia Farmaceutici, SpA
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Flow plans to develop Halo’s transcranial direct current stimulation technology to treat depression and other mental health disorders.
- Other Names / Subsidiaries
- Fidia Pharma Group
- OftaH.T. e Neoox
- Soluciones Bioregenerativas SL
- Sooft Italia
- Fidia Pharma Austria GmbH